UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Volltextzugriff (PDF)

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.27-36.e1

2015

Volltextzugriff (PDF)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.83-98.e4

2016

Volltextzugriff (PDF)

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1176-1182

2014

Volltextzugriff (PDF)

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.448-456

2010

Volltextzugriff (PDF)

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Journal of the American Academy of Dermatology, 2012-08, Vol.67 (2), p.245-256

2012

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Volltextzugriff (PDF)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-06, Vol.156 (6), p.649

2020

Volltextzugriff (PDF)

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

JAMA dermatology (Chicago, Ill.), 2015-09, Vol.151 (9), p.961

2015

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Volltextzugriff (PDF)

Serious adverse events-Missing in action: Comment on the article by Kremer et al

Arthritis & rheumatology (Hoboken, N.J.), 2012-09, Vol.64 (9), p.3055-3056

Leonardi, Craig L.

2012

Volltextzugriff (PDF)

Etanercept as Monotherapy in Patients with Psoriasis

The New England journal of medicine, 2003-11, Vol.349 (21), p.2014-2022

2003

Volltextzugriff (PDF)

Subgroup analyses of etanercept in pediatric patients with psoriasis

Journal of the American Academy of Dermatology, 2010-08, Vol.63 (2), p.e38-e41

2010

Volltextzugriff (PDF)

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Journal of the American Academy of Dermatology, 2005-03, Vol.52 (3), p.425-433

2005

Volltextzugriff (PDF)

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Journal of drugs in dermatology, 2016-05, Vol.15 (5), p.562

2016

Volltextzugriff (PDF)

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Journal of drugs in dermatology, 2013-08, Vol.12 (8), p.888

2013

Volltextzugriff (PDF)

Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database

Journal of the American Academy of Dermatology, 2006-03, Vol.54 (3), p.S92-S100

2006

Volltextzugriff (PDF)

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2006-04, Vol.54 (4), p.S164-S170

2006

Volltextzugriff (PDF)

Current concepts and review of efalizumab in the treatment of psoriasis

Dermatologic clinics, 2004-10, Vol.22 (4), p.427-435

Leonardi, Craig L.

2004

Volltextzugriff (PDF)

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

Journal of drugs in dermatology, 2004-11, Vol.3 (6), p.614

2004

Volltextzugriff (PDF)

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551

2015

Volltextzugriff (PDF)

Persistent CD4+ T cell depression following combination alefacept and methotrexate therapy

International journal of dermatology, 2008-11, Vol.47 (11), p.1204-1206

2008

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(42)
Female
(37)
Science & Technology
(35)
Life Sciences & Biomedicine
(34)
Middle Aged
(33)
Adult
(31)
Dermatology
(29)
Psoriasis - Drug Therapy
(28)
Severity Of Illness Index
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Treatment Outcome
(18)
Aged
(17)
Double-Blind Method
(17)
Psoriasis
(17)
Antibodies, Monoclonal - Adverse Effects
(11)
Antibodies, Monoclonal - Therapeutic Use
(11)
Antibodies, Monoclonal - Administration & Dosage
(10)
Drug Administration Schedule
(10)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Serious adverse events-Missing in action: Comment on the article by Kremer et al

Etanercept as Monotherapy in Patients with Psoriasis

Subgroup analyses of etanercept in pediatric patients with psoriasis

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

Current concepts and review of efalizumab in the treatment of psoriasis

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Persistent CD4+ T cell depression following combination alefacept and methotrexate therapy

Aktive Filter

Suchergebnisse filtern